PLACE OF INHIBITOR-PROTECTED PENICILLINS IN THE TREATMENT OF LOW RESPIRATORY TRACT INFECTIONS. POSITIONS REMAIN UNCHANGED


Cite item

Full Text

Abstract

The main nosological forms of lower respiratory tract infections are infectious exacerbation of chronic bronchitis and chronic obstructive pulmonary disease (COPD), and community-acquired pneumonia (CAP). The major antibacterial drugs (AD) in the treatment of above-mentioned diseases are β-lactam antibiotics (aminopenicillins, including inhibitor-protected penicillins, II - III generation cephalosporins), macrolides, and respiratory fluoroquinolones. Clinical and microbiological efficacy of inhibitor-protected penicillins, macrolides, and respiratory fluoroquinolones is equal. The clinical situation, in particular the severity of COPD exacerbations and severity of CAP, the factors of poor response, the risk of antibiotic resistance, availability of dosing schedule, safety and tolerability of drug should be taking into account before choosing the antibiotics.

References

  1. Чучалин А.Г. и соавт. Внебольничная пневмония у взрослых / Практические рекомендации по диагностике, лечению и профилактике. М., 2010.
  2. Beghi G, Berni F, Carratu L, et al. Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis. J Chemother 1995;7:146-52.
  3. Anzueto A, Fisher CL Jr, Busman T, Olson CA. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin Ther 2001;23:72-86.
  4. Martinot JB, Carr WD, Cullen S, et al. A comparative study of clarithromycin modified release and amoxicillin/clavulanic acid in the treatment of acute exacerbation of chronic bronchitis. Adv Ther 2001;18:1-11.
  5. Hoepelman IM, Mollers MJ, van Schie MH, et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int J Antimicrob Agents 1997;9:141-6.
  6. Martinez FJ, Grossman RF, Zadeikis N, et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J 2005;25:1001-10.
  7. Starakis I, Gogos CA, Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2004;23:129-37.
  8. Schaberg T, Ballin I, Huchon G, et al. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res 2001;29:314-28.
  9. File T, Schlemmer B, Garau J, Lode H, Lynch S, Young C. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group. J Chemother 2000;12:314-32.
  10. Siempos I, Dimopoulos G, Korbila I, Manta K and Falagas M. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007;29:1127-37.
  11. Celli BR, MacNee W, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
  12. Синопальников А.И., Романовских А.Г. Инфекционные обострения хронической обструктивной болезни легких. // Соnsilium medicum 2006. Т. 8. № .1.
  13. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999-2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II // Клин. микробиол. антимикроб. химиотер. 2006. 8(1). С. 33-47.
  14. Pankuch GA, Jueneman SA, Davies TA, Jacobs MR, Appelbaum PC. In vitro selection of resistance to four beta-lactams and azitromycin in S. pneumoniae. Antimicrob Agents Chemother 1998;42:2914-18.
  15. Maimon N, Nopmaneejumruslers C, Marras TK. Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis. Eur Resir J 2008;31:1068-76.
  16. Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med 2005;165(17):1992-2000.
  17. Martinez JA,Horcajada JP, Almela M, еt al. Addition of macrolide to a beta-lactam-baseв empirical antibiotic regimen is associated with lower inhospitality mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389-95.
  18. Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998;30:397-404.
  19. Kahn JB, Wiesinger A, Olson WH, et al. Levofloxacin vs ceftriaxone sodium and erytromycin in the treatment of patients with community-acquired pneumonia at high risk of mortality. Abstracts of 7th International Symposium on New Quinolones. Edinburg, UK 2001;45.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies